Investigating a pathway involved in lung scarring
Targeting the ADAM10-sEphrin-B2 pathway in pulmonary fibrosis
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-10599961
This study is looking into how a specific process in the body contributes to lung scarring in people with pulmonary fibrosis, with the goal of finding new ways to help treat this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10599961 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding pulmonary fibrosis, a serious lung disease that leads to scarring and loss of lung function. The team is exploring the ADAM10-sEphrin-B2 pathway, which plays a crucial role in activating cells that contribute to lung scarring. By identifying how this pathway works, the researchers aim to find new therapeutic targets that could lead to effective treatments for patients suffering from this condition. The approach includes both laboratory studies and analysis of patient samples to uncover the mechanisms behind myofibroblast activation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or other forms of pulmonary fibrosis.
Not a fit: Patients with non-pulmonary fibrosis-related lung conditions or those without significant lung scarring may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent the progression of pulmonary fibrosis, improving patients' quality of life.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for treating fibrosis, indicating potential for success in this approach.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEDOFF, BENJAMIN DAVID — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: MEDOFF, BENJAMIN DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.